If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is the formulation of Zepbound® (tirzepatide) in the vial the same as in the single-dose pen?
The formulation of tirzepatide provided in the single-dose vial is the same as the single-dose pen approved for use in the US.
See important safety information, including boxed warning, in the attached prescribing information.
Tirzepatide Vial Versus Single-Dose Pen Formulation
The formulation of tirzepatide provided in the single-dose vial is the same as the single-dose pen that was tested in the SURMOUNT-1 and -2 phase 3 clinical trials in adults with obesity or overweight.1,2
This includes the same excipients, excipient concentrations, and drug substance concentration.3
Dose strengths, injection volume, and route of administration are also the same.4
Both the tirzepatide single-dose vial and single-dose pen are for single use and do not contain preservatives.4
List of All Ingredients for Tirzepatide Single-Dose Vial and Single-Dose Pen Formulation provides the list of all ingredients in the tirzepatide vial and single-dose pen formulation.
Tirzepatide Ingredientsa |
Quantity (per 0.5 mL) |
Purpose of Ingredient |
Tirzepatide |
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg |
Active Ingredient |
Sodium chloride |
4.1 mg |
Tonicity agent |
Sodium phosphate dibasic |
0.7 mg |
Buffer |
Water for injection to final volume |
As needed to 0.5 mL |
Vehicle |
Hydrochloric acid solution 10% |
as needed |
pH adjustmentb |
aThe list of ingredients and quantity are the same in the tirzepatide vial and single-dose pen presentation.
bTirzepatide has a pH of 6.5 – 7.5.
Enclosed Prescribing Information
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038
2Garvey WT, Frias JP, Jastreboff AM, et al; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. https://doi.org/10.1016/S0140-6736(23)01200-X
3Data on file, Eli Lilly and Company and/or one of its subsidiaries.
4Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: June 07, 2024